Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Small-cell lung cancer (SCLC) is an aggressive neuroendocrine cancer.
• Oncogenic MYC amplifications are known drivers of SCLC heterogeneity and plasticity.
• The genetic mechanisms underlying MYC amplification and SCLC phenotypic plasticity remain largely unknown.

Purpose of the Study:

• To elucidate the genetic mechanisms of MYC amplification in SCLC.
• To understand the role of extrachromosomal DNA (ecDNA) in driving SCLC heterogeneity and phenotypic plasticity.
• To develop noninvasive methods for detecting ecDNA amplifications in SCLC.

Main Methods:

• Whole-genome sequencing
• Long-range optical mapping
• Single-cell DNA sequencing
• Fluorescence in situ hybridization
• Cell-free nucleosome profiling

Main Results:

• Extrachromosomal DNA (ecDNA) is identified as a primary source of oncogene amplifications and driver fusions in SCLC.
• ecDNAs facilitate proximity of enhancer elements and oncogenes, forming transcription-amplifying units that drive high MYC gene dosage.
• Cell-free nucleosome profiling can noninvasively detect ecDNA amplifications in plasma.
• A comprehensive map of SCLC ecDNA is established, revealing a novel mechanism for MYC-driven heterogeneity.

Conclusions:

• ecDNA plays a critical role in the genetic amplification of oncogenes, particularly MYC, in SCLC.
• ecDNA-driven transcriptional flexibility contributes to SCLC phenotypic plasticity and tumor heterogeneity.
• Noninvasive detection of ecDNA in plasma offers a promising avenue for SCLC diagnosis and genomic interrogation.